Mersana Therapeutics (FRA:0M4) Beginning Cash Position : €171.26 Mil (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Mersana Therapeutics Beginning Cash Position?

Mersana Therapeutics's Beginning Cash Position for the quarter that ended in Dec. 2023 was €171.26 Mil.

Mersana Therapeutics's quarterly Beginning Cash Position increased from Jun. 2023 (€113.81 Mil) to Sep. 2023 (€121.07 Mil) and increased from Sep. 2023 (€121.07 Mil) to Dec. 2023 (€171.26 Mil).

Mersana Therapeutics's annual Beginning Cash Position declined from Dec. 2021 (€226.04 Mil) to Dec. 2022 (€168.43 Mil) and declined from Dec. 2022 (€168.43 Mil) to Dec. 2023 (€118.63 Mil).

Mersana Therapeutics Beginning Cash Position Historical Data

The historical data trend for Mersana Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mersana Therapeutics Beginning Cash Position Chart

Mersana Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beginning Cash Position

Get a 7-Day Free Trial

54.01

51.52

226.04

168.43

118.63

Mersana Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Beginning Cash Position	Get a 7-Day Free Trial															174.23	120.83	113.81	121.07	171.26

Mersana Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Mersana Therapeutics Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Mersana Therapeutics's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Mersana Therapeutics (FRA:0M4) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mersana Therapeutics Inc (FRA:0M4) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

MRSN:USA

Address

840 Memorial Drive, Cambridge, MA, USA, 02139

Website

https://www.mersana.com

Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.

Mersana Therapeutics (FRA:0M4) Headlines

No Headlines